Rua Bioscience (RUA) Stock Overview
Engages in the research, development, and sale of pharmaceutical products in New Zealand and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
RUA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Rua Bioscience Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$0.032 |
| 52 Week High | NZ$0.059 |
| 52 Week Low | NZ$0.023 |
| Beta | 0.50 |
| 1 Month Change | -3.03% |
| 3 Month Change | 14.29% |
| 1 Year Change | 14.29% |
| 3 Year Change | -84.39% |
| 5 Year Change | -92.73% |
| Change since IPO | -95.29% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation
May 13
Companies Like Rua Bioscience (NZSE:RUA) Are In A Position To Invest In Growth
Dec 17Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation
Jul 02Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation
Mar 09Shareholder Returns
| RUA | NZ Pharmaceuticals | NZ Market | |
|---|---|---|---|
| 7D | -5.9% | -4.9% | -0.4% |
| 1Y | 14.3% | -14.7% | 7.1% |
Return vs Industry: RUA exceeded the NZ Pharmaceuticals industry which returned -14.7% over the past year.
Return vs Market: RUA exceeded the NZ Market which returned 7.1% over the past year.
Price Volatility
| RUA volatility | |
|---|---|
| RUA Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in NZ Market | 6.5% |
| 10% least volatile stocks in NZ Market | 2.4% |
Stable Share Price: RUA's share price has been volatile over the past 3 months compared to the NZ market.
Volatility Over Time: RUA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of NZ stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Paul Naske | www.ruabio.com |
Rua Bioscience Limited engages in the research, development, and sale of pharmaceutical products in New Zealand and internationally. It offers cannabis-derived medicines. The company is also involved in seed production and genetic discovery related activities.
Rua Bioscience Limited Fundamentals Summary
| RUA fundamental statistics | |
|---|---|
| Market cap | NZ$10.82m |
| Earnings (TTM) | -NZ$3.45m |
| Revenue (TTM) | NZ$2.39m |
Is RUA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RUA income statement (TTM) | |
|---|---|
| Revenue | NZ$2.39m |
| Cost of Revenue | NZ$1.39m |
| Gross Profit | NZ$1.00m |
| Other Expenses | NZ$4.45m |
| Earnings | -NZ$3.45m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 41.88% |
| Net Profit Margin | -144.06% |
| Debt/Equity Ratio | 30.3% |
How did RUA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/06 23:29 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rua Bioscience Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.